Immunotherapy biotech Jounce Therapeutics sets terms for $75 million IPORenaissance CapitalJounce Therapeutics, a early-stage biotech developing T-cell immuno-oncology therapies with Celgene, announced terms for its IPO on Tuesday. The Cambridge, MA-ba… Continue reading
|
Cryoport to Support ProMab Biotechnologies’ CAR-T Cell Preclinical …
Yahoo Finance IRVINE, Calif., Jan. 17, 2017 /PRNewswire/ — Cryoport, Inc. (NASDAQ: CYRX, CYRXW) (“Cryoport” or the “Company”), the world’s leading cryogenic logistics … |
Sports Perspectives |
Abeona Therapeutics to Present at Phacilitate Cell & Gene Therapy World 2017
GlobeNewswire (press release) NEW YORK and CLEVELAND, Jan. 17, 2017 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (NASDAQ:ABEO) a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced … Abeona Therapeutics Inc. (ABEO) Receives Consensus Recommendation of “Buy” from AnalystsThe Cerbat Gem Abeona Therapeutics Inc. (ABEO) Forecasted to Post FY2016 Earnings of ($0.59) Per ShareSports Perspectives |
Sacramento Bee |
California’s stem cell agency will run out of money in three years. Should voters OK spending more?
Sacramento Bee Scientist Donald Kohn of UCLA cured her of the rare affliction by using her own blood stem cells to alter a troublesome gene. It was an experimental treatment not readily available to the public at large. Kohn’s research has been supported with nearly … |
Sci-News.com |
Scientists Use Human Pluripotent Stem Cells to Regenerate …
Sci-News.com A process using human stem cells can generate heart cells belonging to the external layer, the epicardium, according to an international team of scientists from … How to rebuild heart’s layers with stem cells – FuturityFuturity: Research News |